β2-Agonists Improve Nonaerobic Athletic Performance
TUESDAY, Aug. 4, 2020 -- Sprint and strength performance are improved in nonasthmatic athletes by using β2-agonists, according to a review published online Aug. 3 in the British Journal of Sports Medicine.
Amund Riiser, Ph.D., from the Western Norway University of Applied Sciences in Vestlandet, and colleagues conducted a systematic literature review to examine the effect of β2-agonists on anaerobic performance (maximal physical performance lasting one minute or less) in healthy nonasthmatic individuals.
Based on 34 identified studies, the researchers found that β2-agonists improved anaerobic performance by 5 percent, but the effect was related to dose and administration route. The standardized difference in mean (SDM) was 0.14 for approved β2-agonists and 0.46 for prohibited β2-agonists. For inhaled administration, SDM was 0.16 versus 0.51 for oral administration. Additionally, SDM was 0.20 for acute treatment and 0.50 for treatment for multiple weeks. Strength and sprint performance were specifically improved by β2-agonists.
"Our results support that the use of β2-agonists should be controlled and restricted to athletes with documented asthma," the authors write.
© 2021 HealthDay. All rights reserved.
Posted August 2020
Read this next
TUESDAY, July 27, 2021 -- COVID-19 cases in Britain have fallen for six days in a row, even though the government lifted all but a few social-distancing restrictions last...
TUESDAY, July 27, 2021 -- Serious "long COVID" symptoms could qualify as a disability and make patients eligible for federal assistance, President Joe Biden said Monday. Some...
TUESDAY, July 27, 2021 -- The 1993 U.S. Family and Medical Leave Act (FMLA) requirements disproportionately exclude women and Black, indigenous, and multiracial workers, according...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.